Truist Securities Maintains Hold on Sage Therapeutics, Lowers Price Target to $13
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has maintained a Hold rating on Sage Therapeutics (NASDAQ:SAGE) but lowered the price target from $18 to $13.
August 14, 2024 | 2:14 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Truist Securities has maintained a Hold rating on Sage Therapeutics but lowered the price target from $18 to $13.
The lowered price target from $18 to $13 by Truist Securities suggests a less optimistic outlook for Sage Therapeutics, which could negatively impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100